NCT05803382 2026-03-18
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
52 trialsNCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
NCT07432295 2026-02-25
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT03869892 2025-12-22
SOLSTICE
Servier
Phase 3 Active not recruiting
NCT05472948 2025-12-17
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT06090994 2025-05-07
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
Fudan University
Phase 4 Recruiting
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT04534218 2024-12-20
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT01759238 2022-07-01
OLGA
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT02595320 2021-12-20
X7-7
University of Kansas Medical Center
Phase 2 Unknown
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT02550743 2021-03-12
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
Brown University
Phase 1 Terminated
NCT00212615 2020-11-06
XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer
Odense University Hospital
Phase 2/3 Completed
NCT01471353 2020-07-23
SorCape
University of Florida
Phase 2 Completed
NCT04380103 2020-05-08
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT02716766 2020-04-10
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
Phase 2 Completed
NCT00444678 2020-04-03
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
NYU Langone Health
Phase 2 Completed
NCT03634202 2019-05-15
DESIR
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT00483834 2019-02-15
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT01996306 2019-01-08
AXEPT
Epidemiological and Clinical Research Information Network
Phase 3 Completed
NCT01661972 2018-10-29
X-TRAP
Duke University
Phase 1/2 Completed
NCT00408772 2017-06-09
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
Phase 2 Withdrawn
NCT01364493 2017-05-09
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Phase 2 Completed
NCT01640665 2016-09-16
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Yale University
Phase 1 Completed
NCT01130805 2016-04-15
A Study of Pazopanib With CAPEOX in AGC Patients
Samsung Medical Center
Phase 2 Completed
NCT00526669 2016-01-29
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
Phase 2 Completed
NCT01099527 2015-12-29
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
Samsung Medical Center
Phase 1/2 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT01472770 2014-12-04
GemCaP
Vejle Hospital
Phase 2 Completed
NCT00719550 2013-12-05
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Amgen
Phase 1/2 Completed
NCT00268463 2013-05-15
Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer
NSABP Foundation Inc
Phase 3 Terminated
NCT00950820 2013-03-04
VOXEL
AIO-Studien-gGmbH
Phase 2 Terminated
NCT00482222 2013-01-23
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
University of Southampton
Phase 3 Unknown
NCT00118105 2013-01-03
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT01161186 2012-10-11
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed
NCT00561522 2010-07-21
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
Fudan University
Phase 2/3 Unknown
NCT00125021 2009-11-02
Tarceva and Capecitabine for Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00123851 2009-04-28
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00675194 2008-05-20
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT00580359 2008-01-08
S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT00346099 2008-01-07
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
NSABP Foundation Inc
Phase 2 Withdrawn
NCT00120172 2007-11-16
Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer
Geriatric Oncology Consortium
Phase 2 Terminated
NCT00506168 2007-07-25
Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer
National Cancer Center, Korea
Phase 2 Terminated